Stocks cling to gains ahead of slew of cenbank meetings



* European stock rally fizzles; Wall Street futures slip

* Asian shares drop on Omicron fears, ADB growth forecast

* Many traders stick to sidelines ahead of cenbank meetings

* Graphic: Global asset performance Link

* Graphic: World FX rates Link

By Tommy Wilkes

LONDON, Dec 14 (Reuters) - European shares clung to gains on Tuesday while Wall Street looked set to fall, as investors nervously eyed the spread of the Omicron variant of the coronavirus and sat on the sidelines before numerous central bank decisions due this week.

Despite fears that Omicron is spurring another round of government restrictions that will slow economic growth, stock markets have held up well and rebounded fast - the S&P 500 last week enjoyed its strongest week since early February.

There is plenty for investors to be nervous about as policymakers at the U.S. Federal Reserve, the European Central Bank, the Bank of Japan and the Bank of England weigh the pace of interest rate rises needed to curb higher inflation.

But some investors appear happy to 'buy the dip' and move back into stocks, although volumes have also been lower in recent weeks. Many traders are reluctant to take on new positions before year-end after a very strong rally in 2021.

"Everyone has their hands in their pockets at the moment, first because of the major (central bank) events that are coming up and also because most people had a fairly successful year and don't want to blow it at the end of the year," said Colin Asher, Senior Economist at Japanese bank Mizuho.

By 1230 GMT, most early gains in European stocks had fizzled. The EURO STOXX 50 .STOXX was 0.14% higher. German shares .GDAXI were flat but Britain's FTSE 100 .FTSE climbed 0.48%. That followed falls across European markets on Monday when a Wall Street selloff hit sentiment.

Wall Street futures were weaker on Tuesday ESc1 , pointing to a lower open.

Asian shares didn't fare so well. MSCI's broadest index of Asia-Pacific shares outside Japan .MIAPJ0000PUS was down 0.73%, as the Asian Development Bank (ADB) trimmed its growth forecast for developing Asia, reflecting risks brought on by the new virus variant.

China's CSI300 index .CSI300 dropped 0.67%, after health authorities in Tianjin detected the country's first Omicron case.

Hong Kong's Hang Seng Index .HSI weakened 1.55%, also dragged down by persistent concerns over the health of China's property sector.

MSCI's gauge of stocks across the globe .MIWD00000PUS was unchanged on the day.

ELEVATED VOLATILITY

The Fed is expected on Wednesday to signal a faster wind-down of its monthly $120 billion bond-buying programme to combat accelerating inflation, which could move it one step closer to raising interest rates.

The dollar edged marginally higher ahead of the upcoming meetings.

The dollar index =USD was last at 96.382 while versus the euro EUR= it stood $1.1284. The euro is seen as vulnerable given expectations that the Fed will tighten policy faster than the ECB.

"Volatility will remain elevated throughout all of (these) decisions from the Fed, the ECB, and BOE," said Edward Moya, senior analyst at OANDA.

Fears over the Omicron variant of COVID-19 were heightened after British Prime Minister Boris Johnson warned of a "tidal wave" of new cases, and the World Health Organization said it poses a "very high" global risk, with some evidence that it evades vaccine protection.

Oil futures reversed earlier falls as OPEC predicted in its monthly report that the Omicron variant's impact on fuel demand would be mild.

Brent LCOc1 futures rose 0.42% higher at $74.70 a barrel, while U.S. West Texas Intermediate crude CLc1 increased 0.38%, to $71.57.

Oil prices remain way off levels above $85 a barrel seen in mid-October before the variant was discovered.

The benchmark U.S. 10-year Treasury yield traded 1 basis point higher at 1.437% after falling on Monday US10YT=RR as traders positioned for a hawkish Fed.



Emerging markets Link
Global asset performance Link
US PPI Link



Additional reporting by Sujata Rao in London and Paulina Duran
in Sydney; Editing by Giles Elgood and Gareth Jones

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.